XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Xilio Development Inc (XLO) is rated C (2.5/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Growth (A+); its weakest is Profitability (D-). The rating has held at C for 56 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-07-29 | C+ (2.6) | A+ (5.0) | D- (1.0) | C (2.4) | D+ (1.5) | C (2.5) |
| 2025-06-30 | C+ (2.6) | A+ (5.0) | D- (1.0) | C (2.4) | D+ (1.5) | C (2.5) |
| 2025-03-31 | C+ (2.7) | C+ (2.5) | D- (1.1) | C (2.4) | D+ (1.5) | C- (2.0) |
| 2024-12-31 | C+ (2.6) | C+ (2.5) | D- (1.0) | C (2.3) | D (1.5) | C- (2.0) |
| 2024-09-30 | C+ (2.6) | C+ (2.5) | D- (1.0) | C (2.3) | D+ (1.5) | C- (2.0) |